IL158552A0 - Lipids containing omega-3 fatty acids - Google Patents

Lipids containing omega-3 fatty acids

Info

Publication number
IL158552A0
IL158552A0 IL15855203A IL15855203A IL158552A0 IL 158552 A0 IL158552 A0 IL 158552A0 IL 15855203 A IL15855203 A IL 15855203A IL 15855203 A IL15855203 A IL 15855203A IL 158552 A0 IL158552 A0 IL 158552A0
Authority
IL
Israel
Prior art keywords
fatty acids
lipids containing
containing omega
omega
lipids
Prior art date
Application number
IL15855203A
Other languages
English (en)
Original Assignee
Enzymotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzymotec Ltd filed Critical Enzymotec Ltd
Priority to IL15855203A priority Critical patent/IL158552A0/xx
Publication of IL158552A0 publication Critical patent/IL158552A0/xx
Priority to CNA200480038107XA priority patent/CN1897955A/zh
Priority to CN2013102535938A priority patent/CN103381172A/zh
Priority to CA2542504A priority patent/CA2542504C/en
Priority to JP2006536258A priority patent/JP2007509131A/ja
Priority to BRPI0415744A priority patent/BRPI0415744B8/pt
Priority to EP04791827A priority patent/EP1689413A2/de
Priority to AU2004282006A priority patent/AU2004282006C1/en
Priority to EP10180547.1A priority patent/EP2258377B1/de
Priority to KR1020127022875A priority patent/KR20120115419A/ko
Priority to KR1020067007683A priority patent/KR101331658B1/ko
Priority to RU2006116267/15A priority patent/RU2362566C2/ru
Priority to PCT/IL2004/000957 priority patent/WO2005037848A2/en
Priority to US10/994,175 priority patent/US20050130937A1/en
Priority to IL174925A priority patent/IL174925A/en
Priority to US11/414,150 priority patent/US8052992B2/en
Priority to US11/872,440 priority patent/US7968112B2/en
Priority to US11/872,258 priority patent/US20080085319A1/en
Priority to US12/215,080 priority patent/US7935365B2/en
Priority to US12/590,893 priority patent/US8470345B2/en
Priority to JP2012141384A priority patent/JP5835671B2/ja
Priority to IL224977A priority patent/IL224977A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
IL15855203A 2003-10-22 2003-10-22 Lipids containing omega-3 fatty acids IL158552A0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
IL15855203A IL158552A0 (en) 2003-10-22 2003-10-22 Lipids containing omega-3 fatty acids
CN2013102535938A CN103381172A (zh) 2003-10-22 2004-10-21 含ω-3和ω-6脂肪酸的甘油磷脂
KR1020067007683A KR101331658B1 (ko) 2003-10-22 2004-10-21 오메가-3 및 오메가-6 지방산을 함유하는 글리세로인지질
PCT/IL2004/000957 WO2005037848A2 (en) 2003-10-22 2004-10-21 Glycerophospholipids containing omega-3 and omega-6 fatty acids
CA2542504A CA2542504C (en) 2003-10-22 2004-10-21 Lipids containing omega-3 and omega-6 fatty acids
JP2006536258A JP2007509131A (ja) 2003-10-22 2004-10-21 オメガ−３およびオメガ−６脂肪酸を含有するグリセロリン脂質
BRPI0415744A BRPI0415744B8 (pt) 2003-10-22 2004-10-21 uso de uma preparação lipídica contendo ácidos graxos ômega-3 e ômega-6, esta preparação, uso de glicerofosfolipídios, composição nutracêutica e artigo alimentar funcional
EP04791827A EP1689413A2 (de) 2003-10-22 2004-10-21 Glyercophospholipide mit omega-3- und omega-6-fettsäuren
AU2004282006A AU2004282006C1 (en) 2003-10-22 2004-10-21 Glycerophospholipids containing omega-3 and omega-6 fatty acids
EP10180547.1A EP2258377B1 (de) 2003-10-22 2004-10-21 Glycerophospholipide die omega-3 und omega-6 fettsäuren enthalten
KR1020127022875A KR20120115419A (ko) 2003-10-22 2004-10-21 오메가-3 및 오메가-6 지방산을 함유하는 글리세로인지질
CNA200480038107XA CN1897955A (zh) 2003-10-22 2004-10-21 含ω－3和ω－6脂肪酸的甘油磷脂
RU2006116267/15A RU2362566C2 (ru) 2003-10-22 2004-10-21 Липиды, содержащие жирные кислоты омега-3 и омега-6
US10/994,175 US20050130937A1 (en) 2003-10-22 2004-11-19 Lipids containing omega-3 and omega-6 fatty acids
IL174925A IL174925A (en) 2003-10-22 2006-04-11 Glycerophospholipids containing omega-3 and omega-6 fatty acids
US11/414,150 US8052992B2 (en) 2003-10-22 2006-04-28 Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US11/872,440 US7968112B2 (en) 2003-10-22 2007-10-15 Lipids containing omega-3 and omega-6 fatty acids
US11/872,258 US20080085319A1 (en) 2003-10-22 2007-10-15 Lipids containing omega-3 and omega-6 fatty acids
US12/215,080 US7935365B2 (en) 2003-10-22 2008-06-24 Glycerophospholipids for the improvement of cognitive functions
US12/590,893 US8470345B2 (en) 2003-10-22 2009-11-16 Lipids containing omega-3 and omega-6 fatty acids
JP2012141384A JP5835671B2 (ja) 2003-10-22 2012-06-06 オメガ−３おおびオメガ−６脂肪酸を含有するグリセロリン脂質
IL224977A IL224977A (en) 2003-10-22 2013-02-28 Glycerophospholipids containing omega-3 and omega-6 fatty acids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL15855203A IL158552A0 (en) 2003-10-22 2003-10-22 Lipids containing omega-3 fatty acids

Publications (1)

Publication Number Publication Date
IL158552A0 true IL158552A0 (en) 2004-05-12

Family

ID=34044222

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15855203A IL158552A0 (en) 2003-10-22 2003-10-22 Lipids containing omega-3 fatty acids
IL174925A IL174925A (en) 2003-10-22 2006-04-11 Glycerophospholipids containing omega-3 and omega-6 fatty acids
IL224977A IL224977A (en) 2003-10-22 2013-02-28 Glycerophospholipids containing omega-3 and omega-6 fatty acids

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL174925A IL174925A (en) 2003-10-22 2006-04-11 Glycerophospholipids containing omega-3 and omega-6 fatty acids
IL224977A IL224977A (en) 2003-10-22 2013-02-28 Glycerophospholipids containing omega-3 and omega-6 fatty acids

Country Status (10)

Country Link
EP (2) EP1689413A2 (de)
JP (2) JP2007509131A (de)
KR (2) KR20120115419A (de)
CN (2) CN103381172A (de)
AU (1) AU2004282006C1 (de)
BR (1) BRPI0415744B8 (de)
CA (1) CA2542504C (de)
IL (3) IL158552A0 (de)
RU (1) RU2362566C2 (de)
WO (1) WO2005037848A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
IL158553A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Method for preparing phosphatidylserine containing omega-3 acid moieties
US7935365B2 (en) * 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
IL158552A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5697293B2 (ja) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
CA2645123A1 (en) * 2006-02-28 2007-09-07 Bristol-Myers Squibb Company Use of dha and ara in the preparation of a composition for regulating gene expression
JP2008260743A (ja) * 2006-08-03 2008-10-30 Nagase Chemtex Corp Ｎｑｏ１発現増強剤
EP2098229A4 (de) 2006-12-28 2010-03-10 Suntory Holdings Ltd Nervenregenerationsmittel
PL2144618T5 (pl) 2007-03-28 2025-07-21 Aker Biomarine Human Ingredients As Bio-skuteczne kompozycje oleju z kryla
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
WO2009057121A1 (en) * 2007-11-01 2009-05-07 Enzymotec Ltd. Lipid mixture for infant nutrition
US9085527B2 (en) 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
US20130295171A1 (en) 2009-07-23 2013-11-07 U.S NUTRACEUTICALS, LLC d/b/a Valensa International Krill oil and reacted astaxanthin composition and associated method
WO2011050474A1 (en) 2009-10-29 2011-05-05 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
US10052299B2 (en) 2009-10-30 2018-08-21 Retrotope, Inc. Alleviating oxidative stress disorders with PUFA derivatives
CN102753974A (zh) * 2010-02-11 2012-10-24 勒芬天主教大学 磷脂轮廓分析和癌症
WO2011137160A2 (en) * 2010-04-30 2011-11-03 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans
US8663704B2 (en) 2010-04-30 2014-03-04 U.S. Nutraceuticals, LLC Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
US9763897B2 (en) 2010-04-30 2017-09-19 U.S. Nutraceuticals, LLC Therapeutic astaxanthin and phospholipid composition and associated method
RU2467334C2 (ru) * 2010-08-24 2012-11-20 Федеральное государственное бюджетное учреждение "Дальневосточный научный центр физиологии и патологии дыхания" Сибирского отделения РАМН СПОСОБ ОЦЕНКИ МИКРОВЯЗКОСТИ МЕМБРАН ЭРИТРОЦИТОВ ПУТЕМ ВЫЧИСЛЕНИЯ КОЭФФИЦИЕНТА ЭКСИМЕРИЗАЦИИ ПИРЕНА Кэкс У БЕРЕМЕННЫХ, ПЕРЕНЕСШИХ ОБОСТРЕНИЕ ГЕРПЕС-ВИРУСНОЙ ИНФЕКЦИИ В ТРЕТЬЕМ ТРИМЕСТРЕ ГЕСТАЦИИ, С УЧЕТОМ ОПРЕДЕЛЕНИЯ ПРОЦЕНТНОГО СОДЕРЖАНИЯ ОЛЕИНОВОЙ КИСЛОТЫ В МЕМБРАНАХ ЭРИТРОЦИТОВ
GB201016139D0 (en) * 2010-09-24 2010-11-10 Univ Leuven Kath Cancer phosholipidome
WO2012148930A2 (en) 2011-04-26 2012-11-01 Retrotope, Inc. Oxidative retinal diseases
JP6106157B2 (ja) 2011-04-26 2017-03-29 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． 神経変性障害および筋疾患に関与するｐｕｆａ
KR102112087B1 (ko) 2011-04-26 2020-05-18 레트로토프 인코포레이티드 에너지 프로세싱 손상 장애 및 미토콘드리아 결함
JP6145087B2 (ja) 2011-04-26 2017-06-07 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． Ｐｕｆａ酸化関与障害
US8846604B2 (en) 2011-09-02 2014-09-30 Artic Nutrition AS Lipid compositions with high DHA content
BR112014021390A2 (pt) * 2012-02-29 2019-09-24 Braun Melsungen Ag emulsão do tipo óleo em água contendo hormônio e composição farmacêutica
US20150044138A1 (en) * 2012-03-02 2015-02-12 N.V. Nutricia Method for improving functional synaptic connectivity
WO2013136183A2 (en) 2012-03-12 2013-09-19 Innolipid, As Oxidixable fatty acid composition delivery form
AU2013319911B2 (en) 2012-09-19 2016-07-07 Aker Biomarine Antarctic As Omega-3 phospholipid supplements for females
AU2014229540A1 (en) 2013-03-14 2015-10-08 Aker Biomarine Antarctic As Omega- 3 phospholipid supplements for improved brain maturity
CN103242407A (zh) * 2013-05-15 2013-08-14 张雅茹 含多不饱和脂肪酰基的磷脂酰甾醇和/或磷脂酰甾烷醇及制备方法和应用
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
CN103609752B (zh) * 2013-12-02 2016-05-25 内蒙古伊利实业集团股份有限公司 一种改善脑部认知功能的组合物及其制备方法与应用
EP3076978A4 (de) 2013-12-05 2017-08-16 Enzymotec Ltd. Herstellung von seringlycerophospholipid und verfahren zur behandlung von anfällen
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
WO2015181640A1 (en) * 2014-04-30 2015-12-03 Enzymotec Ltd. Krill oil preparations and their uses
US20170360812A1 (en) 2014-11-20 2017-12-21 Enzymotec Ltd. Phospholipid preparations for the improvement of communication skills
EP3256553A2 (de) 2015-02-11 2017-12-20 Aker Biomarine Antarctic AS Lipidzusammensetzungen
ES2937960T5 (en) 2015-02-11 2026-02-16 Aker Biomarine Human Ingredients As Lipid extraction processes
WO2017009711A1 (en) * 2015-07-13 2017-01-19 Enzymotec Ltd. Phospholipid preparations for the improvement of sleep
EP3950649A1 (de) 2015-11-23 2022-02-09 Retrotope, Inc. Ortsspezifische isotopische markierung von 1,4-dien-systemen
KR101744203B1 (ko) * 2016-01-12 2017-06-20 (주)노터스생명과학 포스파티딜콜린을 유효성분으로 포함하는 신장질환 예방 또는 치료용 약학 조성물
EP3426259A4 (de) 2016-03-10 2019-10-09 Enzymotec Ltd. Phospholipidpräparate zur verbesserung der gehirnplastizität
ES2663392B2 (es) * 2016-05-17 2018-09-24 Universidad De La Laguna Complemento nutricional para la protección de neuronas frente al riesgo de Alzheimer y Parkinson en mujeres combinando isoflavonas y ácido docosahexaenoico.
MX385552B (es) 2016-09-29 2025-03-18 Soc Des Produits Nestle S A Star Ácidos grasos omega 3, compuesto que libera no y vitamina b12 como neuroprotector en pacientes sin demencia.
CN109793802A (zh) * 2017-11-16 2019-05-24 西双版纳华坤生物科技有限责任公司 一种用于预防和治疗帕金森症的物质及制备方法和用途
US20210069146A1 (en) * 2018-01-31 2021-03-11 Kinjirushi Co., Ltd. Recognition ability improving agent
EP3750533A4 (de) * 2018-02-09 2021-11-03 Nippon Suisan Kaisha, Ltd. Mittel zur verbesserung des lymphkreislaufs
CN108721269A (zh) * 2018-07-10 2018-11-02 广东海洋大学 一种epa与dha混合剂在防治焦虑和快感缺乏方面的应用
IL295783B2 (en) 2020-02-21 2026-03-01 Retrotope Inc Processes for isotopic alteration of polyunsaturated fatty acids and their derivatives
JP7539076B2 (ja) * 2020-02-29 2024-08-23 国立大学法人九州大学 α－グルコシダーゼ阻害剤
WO2022050355A1 (ja) * 2020-09-04 2022-03-10 国立大学法人千葉大学 ドコサヘキサエン酸、ドコサヘキサエノイル基含有ホスファチジン酸、又はその誘導体によるセロトニントランスポーター関連精神疾患の予防・治療剤
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
US20240138456A1 (en) * 2021-03-05 2024-05-02 Asahi Group Foods, Ltd. Composition containing decomposition product of yeast cell wall, method for producing same, and use thereof
CN113749255B (zh) * 2021-09-15 2022-11-29 江南大学 一种磷脂组合物在修复肌肉损伤的应用
GR20220100576A (el) * 2022-07-13 2024-02-09 Σταυρουλα Κωνσταντινου Μπασακιδου Βρωσιμα ελαια εμπλουτισμενα με θρεπτικα συστατικα για την ενισχυση της λειτουργιας του εγκεφαλου

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54117034A (en) * 1978-02-28 1979-09-11 Nippon Shoji Kk Treating agent for consciousness and perception motion disorder
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
JPH0279311A (ja) * 1988-09-14 1990-03-19 Ngk Insulators Ltd 電気設備の高電圧瑞末部における接地層先端部の電界緩和構造及びその形成方法
JPH03188088A (ja) * 1989-12-15 1991-08-16 Ajinomoto Co Inc 新規リゾホスファチジルセリン
JPH0717855A (ja) * 1992-09-02 1995-01-20 Maruha Corp 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
GB9301629D0 (en) * 1993-01-27 1993-03-17 Scotia Holdings Plc Formulations containing unsaturated fatty acids
JP3467794B2 (ja) * 1993-03-09 2003-11-17 日本油脂株式会社 学習能向上剤
JPH06279311A (ja) * 1993-03-26 1994-10-04 Sagami Chem Res Center プロテインキナーゼｃアイソザイムの活性化剤
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US5716614A (en) * 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
AU2738497A (en) * 1996-04-24 1997-11-12 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US6344482B1 (en) * 1997-04-23 2002-02-05 Andrew L. Stoll Omega-3 fatty acids in the treatment of bipolar disorder
FR2762993B1 (fr) * 1997-05-06 1999-08-13 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
WO2000007577A2 (de) * 1998-08-06 2000-02-17 Wolfgang Stremmel Phosphatidylcholin als arzneimittel mit schleimhautschützender wirkung
WO2004049907A2 (en) * 2002-11-27 2004-06-17 University Of Louisville Research Foundation Compositions and methods for treating transplants
IL158552A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids

Also Published As

Publication number Publication date
JP2012211168A (ja) 2012-11-01
CN103381172A (zh) 2013-11-06
EP1689413A2 (de) 2006-08-16
BRPI0415744B1 (pt) 2018-07-17
EP2258377A2 (de) 2010-12-08
KR20120115419A (ko) 2012-10-17
WO2005037848A2 (en) 2005-04-28
EP2258377B1 (de) 2019-08-28
BRPI0415744B8 (pt) 2021-05-25
EP2258377A3 (de) 2011-10-05
IL174925A0 (en) 2008-02-09
CA2542504A1 (en) 2005-04-28
BRPI0415744A (pt) 2006-12-19
RU2362566C2 (ru) 2009-07-27
AU2004282006A1 (en) 2005-04-28
AU2004282006B2 (en) 2010-04-15
JP5835671B2 (ja) 2015-12-24
WO2005037848A3 (en) 2005-05-26
KR101331658B1 (ko) 2013-11-20
IL224977A (en) 2014-09-30
AU2004282006C1 (en) 2010-10-21
RU2006116267A (ru) 2007-12-10
IL174925A (en) 2014-01-30
KR20060094526A (ko) 2006-08-29
CA2542504C (en) 2014-01-07
CN1897955A (zh) 2007-01-17
JP2007509131A (ja) 2007-04-12

Similar Documents

Publication Publication Date Title
IL158552A0 (en) Lipids containing omega-3 fatty acids
PL1755565T3 (pl) Miękka kapsułka żelatynowa zawierająca wielonienasycony kwas tłuszczowy omega-3
EP1830830A4 (de) Omega-3-fettsäuren und dyslipidämisches mittel für die lipidtherapie
IL180602A0 (en) Composition containing statins and omega-3 fatty acids
AU2003281542A8 (en) Preparation of microbial oil containing polyunsaturated fatty acids
IL172847A0 (en) Method for the production of multiply-unsaturated fatty acids in transgenic organisms
IL192366A0 (en) Omega 3 fatty acid formulations
EP1753298A4 (de) Oxidative stabilisierung von omega-3-fettsäuren in erdnussbutter mit niedrigem linolsäuregehalt
EP1620543A4 (de) Produktion mehrfach ungesättigter fettsäuren in öligen hefen
GB2409644B (en) Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
PL377614A1 (pl) Kompozycje zawierające kwasy tłuszczowe i aminokwasy
IL172617A0 (en) Biaryloxymethylarene-carboxylic acids
PT1656449E (pt) Dessaturases dos ácidos gordos a partir de prímulas
EP1937704A4 (de) Eine c16/18-fettsäureelongase aus mortierella alpina
AU2003217759A8 (en) Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression
EP1709952B8 (de) Zusammensetzung mit polyglycerol/mittelkettigen fettsäureester
GB2405874B (en) Fatty acid ester slip agents for polyethylene terephthalate
AU2003208769A8 (en) Methods for the production of unsaturated fatty acids
EP1617830A4 (de) Veresterte fettsäurezusammensetzung
EP1858352A4 (de) Zusammensetzung umfassend ein pulver enthaltend mikroverkapselte mehrfach ungesättigte langkettige veresterte fettsäuren, die in einem brausegrundstoff verteilt sind
AU2003296701A8 (en) Nematode fatty acid desaturase-like sequences
AU2003241207A1 (en) Process for preparing functional beverage with omega-3 fatty acids
HK1096589A (en) Glycerophospholipids containing omega-3 and omega-6 fatty acids
NO20022578D0 (no) Fosfolipider inneholdende omega-3 fettsyrer
GB0229578D0 (en) Novel method for the production of polyunsaturated fatty acids